The U.S. Court of Appeals for the Federal Circuit (CAFC) on Thursday upheld the District of Delaware’s grant of judgment as a matter of law (JMOL) that Amgen’s patent claims covering its Repatha cholesterol treatment were invalid for lack of enablement. The court found that Amgen’s composition claims were defined by meeting functional limitations, rather than by structure, and that the patent specifications didn’t enable the preparation of the full scope of the claims without undue experimentation. Judge Lourie authored the opinion. Amgen v. Sanofi (CAFC, Feb. 11, 2020)
Recent Posts
- Squires Calls for ‘Born Strong’ Patents in Light of USPTO’s Dire ‘Defective’ Patent Rate
- SAG-AFTRA Says Fortnite’s Use of AI Instead of Actors Is Unfair
- Stewart Clarifies Application of Advanced Bionics, Orders New Briefing in Light of Rescinded Fintiv Memo
- Stewart Issues First Decisions on Discretionary Denial Under Interim Workload Management Process
- Senate IP Subcommittee Talks Legislative Fixes for China’s Threats to American Innovation Leadership